# A Trial of Hetrombopag in Healthy and Hepatic Impairment Subjects

> **NCT05088642** · PHASE1 · COMPLETED · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 24 (actual)

## Conditions studied

- Sever Aplastic Anaemia

## Interventions

- **DRUG:** Hetrombopag Olamine Tablet

## Key facts

- **NCT ID:** NCT05088642
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-28
- **Primary completion:** 2020-12-04
- **Final completion:** 2020-12-04
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2021-10-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05088642

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05088642, "A Trial of Hetrombopag in Healthy and Hepatic Impairment Subjects". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05088642. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*